[1] Siegel R,Naishadham D,Jemal A. Cancer statistics[J]. CA Cancer J Clin, 2013, 63(1):11-30. [2] Zhang XY,Zhang PY. Recent perspectives of epithelial ovarian carcinoma[J]. Oncol Lett, 2016, 12(5):3055-3058. [3] 魏翻艳.FOXM1与卵巢癌关系的研究进展 [J]. 中国妇产科临床杂志,2013,14(5):469-472. [4] 公小迪,姜斌. FOXM1转录因子在肿瘤研究中的新进展[J]. 现代肿瘤医学,2012,20(1):165-168. [5] Yap KL,Fraley SI,Thiaville MM, et al.NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells[J].Cancer Res, 2012,72(16):4085-4096. [6] He SY,Shen HW,Xu L, et al.FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer[J]. Gynecol Oncol, 2012,127(3):601-610. [7] Wang Z,Ahmad A,Li Y, et al.Forkhead box M1 transcription factor:A novel target for cancer therapy[J]. Cancer Treat Rev, 2009,36(2):151-156. [8] Ducreux M, Bennouna J, Adenis A, et al. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer:a phase II COLO-001 trial [J]. Cancer Chemother Pharmacol, 2017, 79(1):9-16. [9] Kim JE, Park YJ. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer [J]. Int J Nanomedicine, 2017, 12:645-658. [10] 许宁,郭志强,殷丽玲. 紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床观察[J]. 当代医学,2011,17(1):134-135. [11] 萨姆布鲁克 J, 拉塞尔 DW著, 黄培堂,等译. 分子克隆实验指南[M].第3版. 2010:75-78. [12] Smolle E, Taucher V, Haybaeck J, et al. Malignant ascites in ovarian cancer and the role of targeted therapeutics[J]. Anticancer Res, 2014, 34(4):1553-1561. [13] Francis RE,Myatt SS,Krol J, et al.FOXM1 is a downstream target and marker of HER2 overexpression in breast cancer[J]. Inter J Oncol, 2009,35(1):57-68. [14] 宫艳秋,韩凤娟,吴效科,等. 卵巢上皮性癌病因学研究进展[J]. 医学研究杂志, 2010,39(1):78-96. [15] Wani MC,Taylor HL,Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia[J]. Am Chem Soc, 1971, 93(9):2317-2325. [16] 罗光华,郭莉莉,刘丽华.紫杉醇与肿瘤免疫的研究进展[J].中国肿瘤生物治疗杂志, 2013,20(2):251-254. [17] Lei KJ, Jia YM, Wang J, et al. Effects of CMNa combined with paclitaxel and carboplatin on elevated CA125 levels in post-operation advanced ovarian cancer patients[J].Chinese-German J Clin Oncol,2008, 7(10): 600-602.
2017, Vol. 24 
